Clinical Trial Update: A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

View source ↗

Summary

A non-interventional post-marketing study assessing outcomes of nitisinone treatment in patients with hereditary tyrosinemia type I, which has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Tyrosinemia Type

Drugs mentioned

• Orfadin (nitisinone)

Snippet

Sponsor: Swedish Orphan Biovitrum | Conditions: Hereditary Tyrosinemia, Type I | Status: WITHDRAWN